• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies

TriMix-MEL (ECI-006), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients

Niel (Belgium), 30 June 2017 – eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence of disease after surgical removal of their tumor, but at risk for disease recurrence.